By Fineline Cube China’s Center for Drug Evaluation (CDE) has published the 107th batch of reference preparations for generic quality and consistency evaluation (GQCE) purposes. The draft opinion is open for public feedback until June 26, 2026, and includes 17 new drugs across 41 specifications, while 5 drugs failed to pass the regulatory review.
Regulatory Update Details
| Item | Detail |
|---|---|
| Batch Number | 107th batch of reference preparations |
| Regulatory Body | Center for Drug Evaluation (CDE), China |
| Program | Generic Quality and Consistency Evaluation (GQCE) |
| Public Comment Period | Open until June 26, 2026 |
| New Additions | 17 drugs, 41 specifications |
| Failed Reviews | 5 drugs |
| Purpose | Establish reference standards for generic drug bioequivalence studies |
GQCE Program Context
- Regulatory Framework: Part of China’s ongoing efforts to ensure generic drugs demonstrate therapeutic equivalence to originator products
- Reference Preparations: Serve as the gold standard against which generic formulations must prove bioequivalence
- Market Impact: Drugs included in the reference preparation list become eligible targets for generic manufacturers seeking market approval
- Quality Standards: Aligns China’s generic drug requirements with international standards (FDA, EMA)
Strategic Implications for Industry
| Stakeholder | Impact |
|---|---|
| Generic Manufacturers | New opportunities to develop biosimilar versions of the 17 newly listed reference drugs |
| Innovator Companies | Increased competition pressure as more products become subject to generic substitution |
| Healthcare System | Potential cost savings through increased availability of therapeutically equivalent generic alternatives |
| Patients | Improved access to affordable medications with guaranteed quality and efficacy standards |
Market Dynamics & Competitive Landscape
- Generic Drug Market: China’s generic pharmaceutical market represents approximately 60% of total prescription volume but faces quality concerns that the GQCE program aims to address
- Regulatory Evolution: The CDE has been systematically expanding the reference preparation list since the GQCE program launch, with over 100 batches now published
- Development Timeline: Generic manufacturers typically require 12-24 months to complete bioequivalence studies and submit applications following reference preparation designation
- Commercial Opportunity: Each newly listed reference preparation represents potential market opportunities worth millions to hundreds of millions of RMB depending on the original drug’s market size
The addition of 17 new drugs to the reference preparation list continues China’s systematic approach to improving generic drug quality while the rejection of 5 drugs demonstrates the CDE’s rigorous evaluation standards.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory developments and market implications. Actual outcomes may differ due to risks including final regulatory decisions, development timelines, and competitive dynamics.-Fineline Info & Tech